| Document And Entity Information - USD ($) $ in Millions | 12 Months Ended | ||
| Dec. 31, 2023 | Apr. 16, 2024 | Jun. 30, 2023 | |
| Document Information Line Items | |||
| Entity Registrant Name | INMUNE BIO INC. | ||
| Trading Symbol | INMB | ||
| Document Type | 10-K/A | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Common Stock, Shares Outstanding | 18,203,393 | ||
| Entity Public Float | $ 106 | ||
| Amendment Flag | true | ||
| Amendment Description | INmune Bio Inc. is filing this Amendment No. 1 on Form 10-K/A, or this Amendment No. 1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, or the Original 10-K, originally filed with the U.S. Securities and Exchange Commission, or SEC, on March 28, 2024, or Original Filing Date, solely for the purpose of including the information required by Items 10 through 14 of Part III of Form 10-K. This information was previously omitted from the Original 10-K in reliance on General Instruction G(3) to Form 10-K, which permits the information in the above referenced items to be incorporated in the Original 10-K by reference from our definitive proxy statement so long as such proxy statement is filed no later than 120 days after our fiscal year-end. We are filing this Amendment No. 1 to include the Part III information in the Original Form 10-K because we will not file a definitive proxy statement containing such information within 120 days after the end of the fiscal year covered by the Original 10-K.This Amendment No. 1 amends and restates in their entirety Items 10 through 14 of the Original 10-K. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, this Amendment No. 1 also contains new certifications by the principal executive officer and the principal financial officer as required by Section 302 of the Sarbanes-Oxley Act of 2002. Accordingly, Item 15 of Part IV is amended to include the currently dated certifications of our principal executive officer and principal financial officer as exhibits. Because no financial statements have been included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. In addition, because no financial statements are included in this Amendment No. 1, new certifications of our principal executive officer and principal financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 are not required to be included with Amendment No. 1.Except as described above, no other changes have been made to the Original 10-K. The Original 10-K continues to speak as of the date of the Original 10-K, and we have not updated the disclosures contained therein to reflect any events that have occurred as of a date subsequent to the date of the Original 10-K. Accordingly, this Amendment No. 1 should be read in conjunction with the Original 10-K. Defined terms used, but not defined, herein have the meanings ascribed to them in the Original 10-K.Unless stated otherwise, references in this Amendment No. 1 to “us,” “we,” “our,” “our Company,” “the Company,” or “INmune Bio” and similar terms refer to INmune Bio Inc. | ||
| Entity Central Index Key | 0001711754 | ||
| Entity Current Reporting Status | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Well-known Seasoned Issuer | No | ||
| Document Period End Date | Dec. 31, 2023 | ||
| Document Fiscal Year Focus | 2023 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | true | ||
| Entity Shell Company | false | ||
| Entity Ex Transition Period | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Entity File Number | 001-38793 | ||
| Entity Incorporation, State or Country Code | NV | ||
| Entity Tax Identification Number | 47-5205835 | ||
| Entity Address, Address Line One | 225 NE Mizner Blvd | ||
| Entity Address, Address Line Two | Suite 640 | ||
| Entity Address, City or Town | Boca Raton | ||
| Entity Address, State or Province | FL | ||
| Entity Address, Postal Zip Code | 33432 | ||
| City Area Code | (858) | ||
| Local Phone Number | 964 3720 | ||
| Title of 12(b) Security | Common Stock ($0.001 par value) | ||
| Security Exchange Name | NASDAQ | ||
| Entity Interactive Data Current | Yes | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Documents Incorporated by Reference [Text Block] | None. | ||
| Auditor Name | Marcum LLP | ||
| Auditor Location | Houston, Texas | ||
| Auditor Firm ID | 688 |
